Backed by:
Team
Sacha Schermerhorn
CEO / Founder
Laura Remesal, PhD
Founding Scientist (Neurobiology)
John Macor, PhD
Diligence Team (Chemistry)
Mike Rowley, PhD, FRSC
Diligence Team (Chemistry)
Bill Greenlee, PhD
Diligence Team (Chemistry)
Dario Doller, PhD
Discovery Team (Chemistry)
Eric Parker, PhD
Diligence Team (Pharmacology)
Ben Buller, PhD
Discovery Team (Pharmacology)
Our team is responsible for:
34
FDA approved medicines
600+
patents
3
ACS Med Chem Hall of Farmers
50+
Clinical candidates
$28B
in total acquisitions
Drugs our team previously discovered:
3rd
most prescribed drug in USA
Lisinopril is a an angiotensin-converting enzyme (ACE) inhibitor and used to treat hypertension, heart failure, and heart attacks. For high blood pressure it is usually a first-line treatment. Lisinopril is also used to prevent kidney problems in people with diabetes mellitus. The drug ranks as the third most prescribed drug in the U.S., with 82.5 million prescriptions in 2022. Developed by Merck and approved in 1987.
Learn More
Bill Greenlee, PhD
Acquired for
$11.6B
Nurtec® ODT, developed by Biohaven and acquired by Pfizer for $11.6 billion in 2022 (via Pfizer’s acquisition of Biohaven), is a calcitonin gene-related peptide (CGRP) receptor antagonist. Approved for acute treatment and prevention of episodic migraines in adults in 2020. Pfizer reported revenue of US$928 million for Nurtec ODT/Vydura in 2023.
Learn More
John Macor, PhD
Acquired for
$3.4B
Xiidra, developed by Shire (later acquired by Takeda) and purchased by Novartis for $3.4 billion in 2019 (Novartis-Takeda deal), is a prescription eye drop approved in 2016 for treating signs and symptoms of dry eye disease in adults (FDA approval announcement). Containing lifitegrast, it targets inflammation by inhibiting T-cell activity, offering relief from dryness and discomfort, often within weeks. Novartis sold it to Bausch + Lomb in 2023 for $1.75 billion, reflecting its $487 million 2022 sales.
Learn More
Michelle Arkin, PhD
Acquired for
$5.1B
Zejula, developed by Tesaro and acquired by GSK for $5.1 billion in 2019 (GSK-Tesaro acquisition), is a PARP inhibitor approved in 2017 for maintenance treatment of recurrent ovarian, fallopian tube, or peritoneal cancer in adults (FDA approval announcement). It targets DNA repair pathways to delay cancer progression and is also approved for first-line maintenance in platinum-responsive advanced ovarian cancer.
Learn More
Mike Rowley, PhD, FRSC
Advisory Board
Steve Holtzman
Business Development
Michelle Arkin, PhD
Chemistry
Matt Krisiloff
Operations / Fundraising